<img src="https://trc.taboola.com/1321591/log/3/unip?en=page_view" width="0" height="0" style="display:none">
Fact Check Library

Fact Check with Logically.

Download the Free App Today

true
true

CLAIM ID

ab19d705

81 percent of non-hospitalized "long-haulers" report cognitive dysfunction.

Non-hospitalized COVID-19 patients with long-term symptoms have a 85 percent chance of reporting cognitive dysfunction.

Non-hospitalized COVID-19 patients with long-term symptoms have a 85 percent chance of reporting cognitive dysfunction.Some COVID-19 patients experience prolonged symptoms over weeks or months. These individuals are sometimes referred to as "long-haulers." Non-hospitalized COVID-19 long haulers reportedly experience neurological symptoms such as cognitive dysfunction and brain fog.

According to a study by the Annals of Clinical and Translational Neurology, the neurological symptoms in long haul COVID-19 can be persistent. Researchers studied 100 people with COVID-19 long-haul from May to November and found 85 percent reported four or more neurologic symptoms.

The study also showed that 81 percent of respondents reported ongoing issues with memory and thinking (brain fog) while 68 percent said they had headaches, and nearly had problems with loss of taste and smell, numbness or tingling, or muscle pain. Less common symptoms included dizziness, blurred vision, and tinnitus.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.

Have a question or correction on one of our fact-checks?

If you think a claim has been misjudged or requires correction, please send us evidence to support your error claim. We will revisit our evidence and verdict and conduct additional research to verify new information.

Fact Check of the Day

misleading

397 children were diagnosed with heart inflammation after receiving Pfizer’s COVID-19 vaccine in U.S.